Jay Dolia, Mahmoud H. Mohammaden, Mohamed A. Tarek, Mateus Damiani, J. Grossberg, A. Pabaney, Michael V. Frankel, D. Jillella, A. Hassan, Wondwossen G. Tekle, Alexandros Georgiadis, Hamzah M Saei, S. Ortega‐Gutierrez, J. Vivanco-Suarez, M. Galecio-Castillo, A. Rodriguez-Calienes, Shahram Majidi, Johanna T. Fifi, S. Matsoukas, James E. Siegler, Mary Penckofer, Ankit Rana, Sunil Sheth, Sergio A. Salazar Marioni, Thanh N. Nguyen, M. Abdalkader, Italo Linfante, G. Dabus, Brijesh P. Mehta, Joy Sessa, M. Jumaa, Rebecca Sugg, Guillermo Linares, A. Al-Bayati, David S. Libeskind, Raul G. Nogueira, Diogo C. Haussen
Rapid expansion of mechanical thrombectomy and swift manufacturing development has translated into significant evolution of large‐bore catheter technology. The objective of this study was to evaluate the association among diverse structural components of large‐bore aspiration catheters on procedural performance. Retrospective analysis of a prospectively maintained mechanical thrombectomy consortium (SVIN [Society of Vascular Interventional Neurology] Registry) treated with stand‐alone contact aspiration for the first pass in the middle cerebral artery M1 or intracranial internal carotid artery occlusions from 2012 to 2021. Catheters were stratified on the basis of construction materials, tip technology, catheter sizing, and catheter lining. Factors associated with first‐pass effect (first‐pass eTICI 2c–3 reperfusion) as well as speed of clot engagement were analyzed. We identified 983 patients with proximal occlusion and aspiration as the first‐pass technique. First‐pass effect was observed in 34% and associated with age (odds ratio [OR], 1.02 [95% CI, 1.01–1.03]), cardioembolic stroke pathogenesis (OR, 1.69 [95% CI, 1.77–2.41]), middle cerebral artery M1 (OR, 2.74 [95% CI, 1.09–1.87]), nongeneral anesthesia (OR, 0.55 [95% CI, 0.39–0.767]), as well as with 0.070‐inch (OR, 2.04 95% CI, 1.01–3.78]), and 0.088‐inch (OR, 3.90 [95% CI, 1.58–9.61]) distal catheter inner diameter in the adjusted analysis. Mean time from arterial access to clot contact was 17 minutes, with faster times observed in younger patients (OR, 0.99 [95% CI, 0.98–0.996]) as well as with the use of aspiration catheters with shorter length of distal outer hydrophilic coating (18–30 cm) on multivariable regression (OR, 0.30 [95% CI, 0.11–0.82]). Larger aspiration catheter distal inner diameter was associated with higher rates of first‐pass effect. Aspiration catheter construction components were found to influence times from arterial access to clot contact.
{"title":"Structural Analysis of Aspiration Catheters and Procedural Outcomes: An Analysis of the SVIN Registry","authors":"Jay Dolia, Mahmoud H. Mohammaden, Mohamed A. Tarek, Mateus Damiani, J. Grossberg, A. Pabaney, Michael V. Frankel, D. Jillella, A. Hassan, Wondwossen G. Tekle, Alexandros Georgiadis, Hamzah M Saei, S. Ortega‐Gutierrez, J. Vivanco-Suarez, M. Galecio-Castillo, A. Rodriguez-Calienes, Shahram Majidi, Johanna T. Fifi, S. Matsoukas, James E. Siegler, Mary Penckofer, Ankit Rana, Sunil Sheth, Sergio A. Salazar Marioni, Thanh N. Nguyen, M. Abdalkader, Italo Linfante, G. Dabus, Brijesh P. Mehta, Joy Sessa, M. Jumaa, Rebecca Sugg, Guillermo Linares, A. Al-Bayati, David S. Libeskind, Raul G. Nogueira, Diogo C. Haussen","doi":"10.1161/svin.123.001214","DOIUrl":"https://doi.org/10.1161/svin.123.001214","url":null,"abstract":"\u0000 \u0000 Rapid expansion of mechanical thrombectomy and swift manufacturing development has translated into significant evolution of large‐bore catheter technology. The objective of this study was to evaluate the association among diverse structural components of large‐bore aspiration catheters on procedural performance.\u0000 \u0000 \u0000 \u0000 Retrospective analysis of a prospectively maintained mechanical thrombectomy consortium (SVIN [Society of Vascular Interventional Neurology] Registry) treated with stand‐alone contact aspiration for the first pass in the middle cerebral artery M1 or intracranial internal carotid artery occlusions from 2012 to 2021. Catheters were stratified on the basis of construction materials, tip technology, catheter sizing, and catheter lining. Factors associated with first‐pass effect (first‐pass eTICI 2c–3 reperfusion) as well as speed of clot engagement were analyzed.\u0000 \u0000 \u0000 \u0000 We identified 983 patients with proximal occlusion and aspiration as the first‐pass technique. First‐pass effect was observed in 34% and associated with age (odds ratio [OR], 1.02 [95% CI, 1.01–1.03]), cardioembolic stroke pathogenesis (OR, 1.69 [95% CI, 1.77–2.41]), middle cerebral artery M1 (OR, 2.74 [95% CI, 1.09–1.87]), nongeneral anesthesia (OR, 0.55 [95% CI, 0.39–0.767]), as well as with 0.070‐inch (OR, 2.04 95% CI, 1.01–3.78]), and 0.088‐inch (OR, 3.90 [95% CI, 1.58–9.61]) distal catheter inner diameter in the adjusted analysis. Mean time from arterial access to clot contact was 17 minutes, with faster times observed in younger patients (OR, 0.99 [95% CI, 0.98–0.996]) as well as with the use of aspiration catheters with shorter length of distal outer hydrophilic coating (18–30 cm) on multivariable regression (OR, 0.30 [95% CI, 0.11–0.82]).\u0000 \u0000 \u0000 \u0000 Larger aspiration catheter distal inner diameter was associated with higher rates of first‐pass effect. Aspiration catheter construction components were found to influence times from arterial access to clot contact.\u0000","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":" 11","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140690047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. R. Knapen, R. B. Goldhoorn, J. Hofmeijer, Geert J. Lycklamaà Nijeholt, R. van den Berg, I. R. van den Wijngaard, R. V. van Oostenbrugge, W. V. van Zwam, C. van der Leij
Balloon guide catheters (BGCs) are used to prevent distal emboli during endovascular treatment for acute ischemic stroke. Although literature reports benefit of BGC, these are not universally used, and randomized head‐to‐head comparisons are lacking. This study compared functional, safety, and technical outcomes between patients treated with non‐BGC and with BGC during endovascular treatment in a nationwide prospective multicenter registry. Patients from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry, 2014 to 2018), who underwent endovascular treatment with a non‐BGC or BGC, were included. Primary outcome was the modified Rankin Scale score at 90 days, and secondary outcomes included procedure time and first‐attempt successful reperfusion (extended Thrombolysis in Cerebral Infarction ≥2C). Treatment‐effect modification and subgroups were analyzed according to first‐line thrombectomy technique and different sizes of non‐BGC. In total 2808 patients were included, and 1671 (60%) were treated with BGC. No differences in the modified Rankin Scale score at 90 days were seen between non‐BGC and BGC groups (adjusted common odds ratio [OR], 0.98 [95% CI, 0.82–1.10]). The non‐BGC was associated with faster procedure times compared with BGC (adjusted β: −2.99 [95% CI, −5.58 to −0.40]). A significant treatment effect was found between BGC use and thrombectomy technique. In subgroup analyses with stent retriever as first‐line technique, 90‐day modified Rankin Scale scores were significantly higher (more disability) in the non‐BGC group compared with the BGC group (adjusted common OR, 0.79 [95% CI, 0.65–0.96]). Direct aspiration combined with non‐BGC resulted in higher first‐attempt rates compared with BGC (adjusted OR, 1.55 [95% CI, 1.06–2.28]). This large prospective multicenter registry showed no differences in clinical outcome between patients treated with non‐BGC and BGC. Subgroup analyses suggest that BGC outperforms the non‐BGC when stent retriever is used as first‐line technique, whereas non‐BGC outperforms the BGC when aspiration is used.
{"title":"Balloon Guide Catheter Versus Non–Balloon Guide Catheter: A MR CLEAN Registry Analysis","authors":"R. R. Knapen, R. B. Goldhoorn, J. Hofmeijer, Geert J. Lycklamaà Nijeholt, R. van den Berg, I. R. van den Wijngaard, R. V. van Oostenbrugge, W. V. van Zwam, C. van der Leij","doi":"10.1161/svin.123.001103","DOIUrl":"https://doi.org/10.1161/svin.123.001103","url":null,"abstract":"\u0000 \u0000 Balloon guide catheters (BGCs) are used to prevent distal emboli during endovascular treatment for acute ischemic stroke. Although literature reports benefit of BGC, these are not universally used, and randomized head‐to‐head comparisons are lacking. This study compared functional, safety, and technical outcomes between patients treated with non‐BGC and with BGC during endovascular treatment in a nationwide prospective multicenter registry.\u0000 \u0000 \u0000 \u0000 Patients from the MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands) Registry, 2014 to 2018), who underwent endovascular treatment with a non‐BGC or BGC, were included. Primary outcome was the modified Rankin Scale score at 90 days, and secondary outcomes included procedure time and first‐attempt successful reperfusion (extended Thrombolysis in Cerebral Infarction ≥2C). Treatment‐effect modification and subgroups were analyzed according to first‐line thrombectomy technique and different sizes of non‐BGC.\u0000 \u0000 \u0000 \u0000 In total 2808 patients were included, and 1671 (60%) were treated with BGC. No differences in the modified Rankin Scale score at 90 days were seen between non‐BGC and BGC groups (adjusted common odds ratio [OR], 0.98 [95% CI, 0.82–1.10]). The non‐BGC was associated with faster procedure times compared with BGC (adjusted β: −2.99 [95% CI, −5.58 to −0.40]). A significant treatment effect was found between BGC use and thrombectomy technique. In subgroup analyses with stent retriever as first‐line technique, 90‐day modified Rankin Scale scores were significantly higher (more disability) in the non‐BGC group compared with the BGC group (adjusted common OR, 0.79 [95% CI, 0.65–0.96]). Direct aspiration combined with non‐BGC resulted in higher first‐attempt rates compared with BGC (adjusted OR, 1.55 [95% CI, 1.06–2.28]).\u0000 \u0000 \u0000 \u0000 This large prospective multicenter registry showed no differences in clinical outcome between patients treated with non‐BGC and BGC. Subgroup analyses suggest that BGC outperforms the non‐BGC when stent retriever is used as first‐line technique, whereas non‐BGC outperforms the BGC when aspiration is used.\u0000","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"18 8","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140693112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Is Mortality the Worst Outcome After Stroke?","authors":"Sunil A. Sheth","doi":"10.1161/svin.124.001332","DOIUrl":"https://doi.org/10.1161/svin.124.001332","url":null,"abstract":"","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"123 s1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140693637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Collaterals, Thrombolysis, Thrombectomy, and More in 2024: Diagonal Translation in Acute Ischemic Stroke","authors":"David S. Liebeskind","doi":"10.1161/svin.124.001389","DOIUrl":"https://doi.org/10.1161/svin.124.001389","url":null,"abstract":"","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":" 18","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140691182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mohammad AlMajali, Mahmoud Dibas, Malik Ghannam, M. Galecio-Castillo, Abdullah Al Qudah, Farid Khasiyev, J. Vivanco-Suarez, A. Rodriguez-Calienes, M. Farooqui, Sophie Shogren, Fawaz AlMajali, Albert Yoo, Edgar A. Samaniego, T. Jovin, A. Sarraj, S. Ortega‐Gutierrez
The available evidence supporting the use of endovascular thrombectomy (EVT) in acute ischemic stroke patients with large core has increased with the recent release of the Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke (TESLA), Efficacy and Safety of Thrombectomy In Stroke with Extended Lesion and Extended Time Window (TENSION), and Large Stroke Therapy Evaluation (LASTE) trials, providing critical information on additional subgroups not included in initial trials. We aimed to study the efficacy and safety of EVT in patients with acute ischemic stroke with large core and stratify by several subgroups including core infarct at presentation, using a comprehensive meta‐analysis of aggregate data. We executed a systematic search to identify randomized controlled trials that compared EVT to medical management (MM) for the treatment of patients with acute ischemic stroke with large core, defined as Alberta Stroke Program Early CT [Computed Tomography] Score ≤5 on noncontrast CT and/or estimated ischemic core ≥50 mL on CT‐perfusion/MR diffusion. The primary outcome was the shift analysis in the 90‐day modified Rankin scale (mRS) score. Secondary outcomes included functional independence (mRS score 0–2), independent ambulation (mRS score 0–3), 90‐day mortality, and symptomatic intracranial hemorrhage. Pooled odds ratios were calculated for shift mRS score through the random‐effects meta‐analyses, and risk ratios (RRs) were used for the other outcomes, comparing EVT with MM alone. Out of 3402 titles and abstracts screened, 6 randomized controlled trials with 1886 patients were included. The EVT group had a higher shift toward a lower mRS than MM alone (odds ratio [OR], 1.49 [95% CI, 1.24–1.79]). Furthermore, the use of EVT was associated with higher rates of functional independence (19.5% versus 7.5%, RR, 2.49 [95% CI, 1.92–3.24]), independent ambulation (36.5% versus 19.9%, RR, 1.91 [95% CI, 1.51–2.43]), and symptomatic intracranial hemorrhage (5.5% versus 3.2%, RR, 1.73 [95% CI, 1.01–2.95]) compared with MM. There was no difference between the 2 groups regarding mortality (31.5% versus 36.8%, RR, 0.86 [95% CI, 0.72–1.02]). Importantly, EVT was consistently associated with a shift toward a lower mRS score in both Alberta Stroke Program Early CT Score 3–5 (OR, 1.60 [95% CI, 1.10–2.32]) and Alberta Stroke Program Early CT Score 0–2 (OR, 1.45 [95% CI, 1.17–1.80]) when compared with MM alone. Our results confirm the efficacy of EVT for acute ischemic stroke with large core and suggest a consistent benefit across all Alberta Stroke Program Early CT Score categories. These results represent an important shift in the current large vessel occlusion selection paradigm that currently considers core as an effect modifier for EVT selection.
{"title":"Does the Ischemic Core Really Matter? An Updated Systematic Review and Meta‐Analysis of Large Core Trials After TESLA, TENSION, and LASTE","authors":"Mohammad AlMajali, Mahmoud Dibas, Malik Ghannam, M. Galecio-Castillo, Abdullah Al Qudah, Farid Khasiyev, J. Vivanco-Suarez, A. Rodriguez-Calienes, M. Farooqui, Sophie Shogren, Fawaz AlMajali, Albert Yoo, Edgar A. Samaniego, T. Jovin, A. Sarraj, S. Ortega‐Gutierrez","doi":"10.1161/svin.123.001243","DOIUrl":"https://doi.org/10.1161/svin.123.001243","url":null,"abstract":"\u0000 \u0000 The available evidence supporting the use of endovascular thrombectomy (EVT) in acute ischemic stroke patients with large core has increased with the recent release of the Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke (TESLA), Efficacy and Safety of Thrombectomy In Stroke with Extended Lesion and Extended Time Window (TENSION), and Large Stroke Therapy Evaluation (LASTE) trials, providing critical information on additional subgroups not included in initial trials. We aimed to study the efficacy and safety of EVT in patients with acute ischemic stroke with large core and stratify by several subgroups including core infarct at presentation, using a comprehensive meta‐analysis of aggregate data.\u0000 \u0000 \u0000 \u0000 We executed a systematic search to identify randomized controlled trials that compared EVT to medical management (MM) for the treatment of patients with acute ischemic stroke with large core, defined as Alberta Stroke Program Early CT [Computed Tomography] Score ≤5 on noncontrast CT and/or estimated ischemic core ≥50 mL on CT‐perfusion/MR diffusion. The primary outcome was the shift analysis in the 90‐day modified Rankin scale (mRS) score. Secondary outcomes included functional independence (mRS score 0–2), independent ambulation (mRS score 0–3), 90‐day mortality, and symptomatic intracranial hemorrhage. Pooled odds ratios were calculated for shift mRS score through the random‐effects meta‐analyses, and risk ratios (RRs) were used for the other outcomes, comparing EVT with MM alone.\u0000 \u0000 \u0000 \u0000 Out of 3402 titles and abstracts screened, 6 randomized controlled trials with 1886 patients were included. The EVT group had a higher shift toward a lower mRS than MM alone (odds ratio [OR], 1.49 [95% CI, 1.24–1.79]). Furthermore, the use of EVT was associated with higher rates of functional independence (19.5% versus 7.5%, RR, 2.49 [95% CI, 1.92–3.24]), independent ambulation (36.5% versus 19.9%, RR, 1.91 [95% CI, 1.51–2.43]), and symptomatic intracranial hemorrhage (5.5% versus 3.2%, RR, 1.73 [95% CI, 1.01–2.95]) compared with MM. There was no difference between the 2 groups regarding mortality (31.5% versus 36.8%, RR, 0.86 [95% CI, 0.72–1.02]). Importantly, EVT was consistently associated with a shift toward a lower mRS score in both Alberta Stroke Program Early CT Score 3–5 (OR, 1.60 [95% CI, 1.10–2.32]) and Alberta Stroke Program Early CT Score 0–2 (OR, 1.45 [95% CI, 1.17–1.80]) when compared with MM alone.\u0000 \u0000 \u0000 \u0000 Our results confirm the efficacy of EVT for acute ischemic stroke with large core and suggest a consistent benefit across all Alberta Stroke Program Early CT Score categories. These results represent an important shift in the current large vessel occlusion selection paradigm that currently considers core as an effect modifier for EVT selection.\u0000","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"35 s141","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140694625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
David S. Liebeskind, Muhammad Bilal Tariq, Naoki Kaneko, J. Hinman
{"title":"The Future of Endovascular Therapy for Intracranial Atherosclerotic Disease","authors":"David S. Liebeskind, Muhammad Bilal Tariq, Naoki Kaneko, J. Hinman","doi":"10.1161/svin.124.001053","DOIUrl":"https://doi.org/10.1161/svin.124.001053","url":null,"abstract":"","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"68 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140704775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Endovascular mechanical thrombectomy (EVT) drastically reduces disability after acute ischemic stroke due to large‐vessel occlusion, but only a small proportion of patients with stroke are eligible for this powerful treatment. Several ongoing studies are aiming to expand the indications for EVT to further reduce disability after acute ischemic stroke for a larger proportion of patients suffering from large‐vessel occlusion stroke. Patients with preexisting disability, comprising ≈30% of all patients with acute ischemic stroke, were universally excluded from the landmark clinical trials that established EVT efficacy. These patients disproportionally suffer from accumulated disability after stroke, with substantial societal and economic impact. Further, there is significant heterogeneity in current practice of EVT among patients with preexisting disability. Establishing evidence‐based acute stroke treatments for this population is a priority. In this narrative review, we summarize the current literature regarding EVT in patients with preexisting disability. While doing so, we highlight key concepts regarding statistical analysis and discuss opportunities and challenges for future studies focusing on this vulnerable population.
{"title":"Endovascular Thrombectomy in Patients With Preexisting Disability: A Review","authors":"Paul M. Wechsler, T. Leslie-Mazwi, Eva A. Mistry","doi":"10.1161/svin.124.001326","DOIUrl":"https://doi.org/10.1161/svin.124.001326","url":null,"abstract":"Endovascular mechanical thrombectomy (EVT) drastically reduces disability after acute ischemic stroke due to large‐vessel occlusion, but only a small proportion of patients with stroke are eligible for this powerful treatment. Several ongoing studies are aiming to expand the indications for EVT to further reduce disability after acute ischemic stroke for a larger proportion of patients suffering from large‐vessel occlusion stroke. Patients with preexisting disability, comprising ≈30% of all patients with acute ischemic stroke, were universally excluded from the landmark clinical trials that established EVT efficacy. These patients disproportionally suffer from accumulated disability after stroke, with substantial societal and economic impact. Further, there is significant heterogeneity in current practice of EVT among patients with preexisting disability. Establishing evidence‐based acute stroke treatments for this population is a priority. In this narrative review, we summarize the current literature regarding EVT in patients with preexisting disability. While doing so, we highlight key concepts regarding statistical analysis and discuss opportunities and challenges for future studies focusing on this vulnerable population.","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140711139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A. Niktabe, J. C. Martinez‐Gutierrez, S. Salazar‐Marioni, R. Abdelkhaleq, Juan Carlos Rodriguez Quintero, J. Jeevarajan, M. Tariq, Ananya S Iyyangar, Hussain M Azeem, A. Ballekere, N. M. Le, Louise D McCullough, Sunil A. Sheth, Youngran Kim
Computed tomography perfusion (CTP) predictions of infarct core play an important role in the determination of treatment eligibility in large‐vessel occlusion acute ischemic stroke. Prior studies have demonstrated that blood glucose can affect cerebral blood flow. Here, we examine the influence of acute and chronic hyperglycemia on CTP estimations of infarct core. From our prospectively collected multicenter observational cohort, we identified patients with large‐vessel occlusion acute ischemic stroke who underwent CTP with RAPID (IschemaView, Stanford, CA) postprocessing, followed by endovascular therapy with substantial reperfusion (Thrombolysis in Cerebral Infarction 2b–3) within 90 minutes, and final infarct volume determination by magnetic resonance imaging 48 to 72 hours posttreatment. Core volume overestimations and underestimations were defined as a difference of at least 20 mL between CTP‐RAPID predicted infarct core and Diffusion Weighted Imaging (DWI) final infarct volume. Primary outcome was the association of presentation glucose and hemoglobin A1c (HgbA1c) with underestimation of core volume and was measured using multivariable logistic regression adjusted for comorbidities and presentation characteristics. Secondary outcomes included frequency of overestimation of infarct core. Among 256 patients meeting inclusion criteria, median age was 67 (interquartile range [IQR], 57–77) years, 51.6% were women, and 132 (51.6%) and 93 (36.3%) had elevated presentation glucose and elevated HgbA1c, respectively. Median CTP‐predicted core was 6 mL (IQR, 0–30 mL), median DWI final infarct volume was 14 mL (IQR, 6‐43 mL), and median difference was 12 mL (IQR, 5–35 mL). Twenty‐eight (10.9%) patients had infarct core overestimation and 68 (26.6%) had underestimation. Compared with those with no underestimation, patients with underestimation had elevated blood glucose (median, 119 [IQR, 103–155] versus 138 [IQR, 117–195] mg/dL; P = 0.002) and HgbA1c (median, 5.80% [IQR, 5.40–6.40] versus 6.40% [IQR, 5.50–7.90]; P = 0.009). In multivariable analysis, underestimation was independently associated with elevated glucose (adjusted odds ratio [OR], 2.10; P = 0.038) and HgbA1c (adjusted OR, 2.37; P = 0.012). Overestimation was associated with lower presentation blood glucose (median, 109 [IQR, 99–132] in overestimation versus 127 [IQR, 107–172] mg/dL in no overestimation; P = 0.003) and HgbA1c (5.6%[IQR 5.1–6.2] in overestimation versus 5.90%[IQR, 5.50–6.70] in no overestimation; P = 0.012). Acute and chronic hyperglycemia were strongly associated with CTP underestimation in patients with large‐vessel occlusion acute ischemic stroke undergoing endovascular therapy. Glycemic state should be considered when interpreting CTP findings in patients with large‐vessel occlusion acute ischemic stroke.
{"title":"Hyperglycemia Is Associated With Computed Tomography Perfusion Core Volume Underestimation in Patients With Acute Ischemic Stroke With Large‐Vessel Occlusion","authors":"A. Niktabe, J. C. Martinez‐Gutierrez, S. Salazar‐Marioni, R. Abdelkhaleq, Juan Carlos Rodriguez Quintero, J. Jeevarajan, M. Tariq, Ananya S Iyyangar, Hussain M Azeem, A. Ballekere, N. M. Le, Louise D McCullough, Sunil A. Sheth, Youngran Kim","doi":"10.1161/svin.123.001278","DOIUrl":"https://doi.org/10.1161/svin.123.001278","url":null,"abstract":"\u0000 \u0000 Computed tomography perfusion (CTP) predictions of infarct core play an important role in the determination of treatment eligibility in large‐vessel occlusion acute ischemic stroke. Prior studies have demonstrated that blood glucose can affect cerebral blood flow. Here, we examine the influence of acute and chronic hyperglycemia on CTP estimations of infarct core.\u0000 \u0000 \u0000 \u0000 From our prospectively collected multicenter observational cohort, we identified patients with large‐vessel occlusion acute ischemic stroke who underwent CTP with RAPID (IschemaView, Stanford, CA) postprocessing, followed by endovascular therapy with substantial reperfusion (Thrombolysis in Cerebral Infarction 2b–3) within 90 minutes, and final infarct volume determination by magnetic resonance imaging 48 to 72 hours posttreatment. Core volume overestimations and underestimations were defined as a difference of at least 20 mL between CTP‐RAPID predicted infarct core and Diffusion Weighted Imaging (DWI) final infarct volume. Primary outcome was the association of presentation glucose and hemoglobin A1c (HgbA1c) with underestimation of core volume and was measured using multivariable logistic regression adjusted for comorbidities and presentation characteristics. Secondary outcomes included frequency of overestimation of infarct core.\u0000 \u0000 \u0000 \u0000 \u0000 Among 256 patients meeting inclusion criteria, median age was 67 (interquartile range [IQR], 57–77) years, 51.6% were women, and 132 (51.6%) and 93 (36.3%) had elevated presentation glucose and elevated HgbA1c, respectively. Median CTP‐predicted core was 6 mL (IQR, 0–30 mL), median DWI final infarct volume was 14 mL (IQR, 6‐43 mL), and median difference was 12 mL (IQR, 5–35 mL). Twenty‐eight (10.9%) patients had infarct core overestimation and 68 (26.6%) had underestimation. Compared with those with no underestimation, patients with underestimation had elevated blood glucose (median, 119 [IQR, 103–155] versus 138 [IQR, 117–195] mg/dL;\u0000 P\u0000 = 0.002) and HgbA1c (median, 5.80% [IQR, 5.40–6.40] versus 6.40% [IQR, 5.50–7.90];\u0000 P\u0000 = 0.009). In multivariable analysis, underestimation was independently associated with elevated glucose (adjusted odds ratio [OR], 2.10;\u0000 P\u0000 = 0.038) and HgbA1c (adjusted OR, 2.37;\u0000 P\u0000 = 0.012). Overestimation was associated with lower presentation blood glucose (median, 109 [IQR, 99–132] in overestimation versus 127 [IQR, 107–172] mg/dL in no overestimation;\u0000 P\u0000 = 0.003) and HgbA1c (5.6%[IQR 5.1–6.2] in overestimation versus 5.90%[IQR, 5.50–6.70] in no overestimation;\u0000 P\u0000 = 0.012).\u0000 \u0000 \u0000 \u0000 \u0000 Acute and chronic hyperglycemia were strongly associated with CTP underestimation in patients with large‐vessel occlusion acute ischemic stroke undergoing endovascular therapy. Glycemic state should be considered when interpreting CTP findings in patients with large‐vessel occlusion acute ischemic stroke.\u0000","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"70 S1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140709648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Meschia, Lloyd J. Edwards, Gary Roubin, Thomas G. Brott, B. Lal
Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2) ( study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators. The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices. The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial. The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.
{"title":"CREST‐2 Commitment to Rigorous Assessment of Carotid Stenting for Primary Prevention of Stroke","authors":"J. Meschia, Lloyd J. Edwards, Gary Roubin, Thomas G. Brott, B. Lal","doi":"10.1161/svin.123.001227","DOIUrl":"https://doi.org/10.1161/svin.123.001227","url":null,"abstract":"\u0000 \u0000 \u0000 Rather than considering carotid stenting and endarterectomy to be rival procedures, they ought to be seen as complementary, with some patients more suited to one procedure over another. The respective patient populations best suited for optimal outcomes with stenting and endarterectomy differ substantially. Hence, the CREST‐2 (Carotid Revascularization, Endarterectomy Versus Stent Trial‐2)\u0000 (\u0000 study was designed as 2 separate 2‐arm randomized trials run in parallel. One trial compares intensive medical management with and without stenting; the other, intensive medical management with and without endarterectomy. Each trial has a recruitment target of 1240 patients with ≥70% asymptomatic carotid stenosis, randomized 1:1 in each arm. To ensure patient safety and give stenting the best possible chance of demonstrating net benefits in stroke prevention, CREST‐2 adopted a rigorous procedure for evaluating, monitoring, and approving operators to enroll in the trial. The CREST‐2 Registry was established to allow for recent experience for applicant stent operators.\u0000 \u0000 \u0000 \u0000 \u0000 The CREST‐2 Registry is a prospective, multicenter, short‐term observational study of carotid stenting allowing use of multiple devices.\u0000 \u0000 \u0000 \u0000 The registry enrolled its first patient in September 2014, and as of October 2, 2023, a total of 9830 patients have been treated by 207 different stent operators from 103 different clinical centers. In this mixed cohort of asymptomatic (61.1% of the cohort) and symptomatic (38.9%) patients, the 30‐day stroke rate is 1.8% and the combined 30‐day stroke or death rate is 2.6%. At its peak in March 2016, the registry achieved an enrollment rate of 142 cases/month. As of October 20, 2023, a total of 104 patients remain to be enrolled in the CREST‐2 stenting trial.\u0000 \u0000 \u0000 \u0000 The registry has facilitated assembly of a high‐performing team of stent operators for the CREST‐2 trial. With continued support of the many operators, we anticipate completing enrollment by the summer of 2024.\u0000","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"66 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140740775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aaron Brake, Lane Fry, Hira Chouhdry, Sivani Lingam, Tara Samiee, Romil Singh, K. Ebersole, Michael G. Abraham
{"title":"Trends of Intravenous Thrombolysis and Thrombectomy for Low NIHSS Score (<6) Strokes in the United States: A National Inpatient Sample Study","authors":"Aaron Brake, Lane Fry, Hira Chouhdry, Sivani Lingam, Tara Samiee, Romil Singh, K. Ebersole, Michael G. Abraham","doi":"10.1161/svin.123.001262","DOIUrl":"https://doi.org/10.1161/svin.123.001262","url":null,"abstract":"","PeriodicalId":21977,"journal":{"name":"Stroke: Vascular and Interventional Neurology","volume":"166 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140748604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：